Dr. Leonard Schleifer
Board Co-Chair, Co-Founder, President and Chief Executive Officer
Replay available
Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Q4 2025 earnings conference call, held 2026-01-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. George Yancopoulos
Board Co-Chair, Co-Founder, President and Chief Scientific Officer
Marion McCourt
Executive Vice President of Commercial
Chris Fethmore
Executive Vice President and Chief Financial Officer
Alexandria Hammond
Analyst, Wolf Research
Chris Raymond
Analyst, Raymond James
Salvin Richter
Analyst, Goldman Sachs
Tyler Van Buren
Analyst, TD Cowen
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Regeneron Pharmaceuticals, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:04.996 Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President 00:00:04.996 -- 00:00:10.120 and Chief Executive Officer, Dr. George Yancopoulos, Board Co-Chair, Co-Founder, President 00:00:10.120 -- 00:00:15.185 and Chief Scientific Officer, Marion McCourt, Executive Vice President of Commercial, 00:00:15.185 -- 00:00:20.109 and Chris Fethmore, Executive Vice President and Chief Financial Officer. 00:00:20.109 -- 00:00:25.314 After our prepared remarks, the remaining time will be available for your Q&A. 00:00:25.314 -- 00:00:28.597 I would like to remind you the remarks made on today's call may include forward-looking 00:00:28.597 -- 00:00:32.721 statements about Regeneron. Such statements may include but are not limited to those 00:00:32.721 -- 00:00:38.067 related to Regeneron and its products and business, financial forecasting guidance, development 00:00:38.067 -- 00:00:43.294 programs and related anticipated milestones, collaborations, finances, regulatory matters, 00:00:43.294 -- 00:00:47.138 payer coverage and reimbursement, intellectual property, pending litigation and other 00:00:47.138 -- 00:00:49.401 proceedings, and competition. 00:00:49.401 -- 00:00:53.145 Each forward-looking statement is subject to risks and uncertainties that could cause 00:00:53.145 -- 00:00:58.098 actual results and events to differ materially from those projected in that statement. 00:00:58.098 -- 00:01:02.282 A more complete description of these and other material risks can be found in Regeneron's 00:01:02.282 -- 00:01:07.266 filings with the United States Securities Exchange Commission, including its Form 10-K 00:01:07.266 -- 00:01:10.928 for the year ended December 31, 2025, 00:01:11.230 -- 00:01:14.713 which we pl...